“Rising Focus on Targeted Therapies”
A key trend boosting the pheochromocytoma market is the increasing focus on targeted therapies. Targeted treatments such as tyrosine kinase inhibitors (such as sunitinib) and peptide receptor radionuclide therapy (PRRT) are gaining traction for their ability to treat advanced cases with high precision and fewer side effects. For instance, PRRT using radiolabeled somatostatin analogs such as Lutathera has shown significant efficacy in metastatic pheochromocytoma patients. In addition, advancements in genomic profiling enable the identification of specific mutations such as RET and SDH genes, guiding personalized treatment strategies. The growing adoption of these cutting-edge approaches ensures better patient outcomes and fuels the market's expansion globally.
